gnf-2

GNF-2 is a highly selective non-ATP competitive inhibitor of Bcr-Abl.

GNF-5 is a specific non-ATP competitive inhibitor of Bcr-Abl (IC50: 0.22±0.1 uM, Wild-type Abl). It is an analog of GNF-2 with improved pharmacokinetic properties.

GNF-2-deg is a PROTAC degrader that targets the envelope protein of the dengue virus (DENV E protein), achieving a DC50 of 0.83 μM. It inhibits viral entry by preventing membrane fusion mediated by the E protein and demonstrates antiviral activity against DENV 2 through protein degradation, with an EC90 of 3.5 μM. Additionally, GNF-2-deg shows antiviral efficacy against ZIKV, JEV, WNV, and YFV, with EC90 values ranging from 1.96 to 7.79 μM.

GNF2133 is an effective and selective inhibitor of DYRK1A with IC50s of 6.2 nM. GNF2133 can be used in studies about type 1 diabetes.

GNF2133 hydrochloride is a selective, effective, and orally active DYRK1A inhibitor, able to act on DYRK1A (IC50: 0.0062 μM) and GSK3β (IC50> 50 μM); GNF2133 hydrochloride showed good proliferative ability and efficacy in rat and human primary β cells. GNF2133 hydrochloride significantly improved glucose processing ability and increased insulin secretion. GNF2133 hydrochloride has the potential to study type 1 diabetes.

GNF-PF-3777 (8-Nitrotryptanthrin) is a potent inhibitor of human indoleamine 2,3-dioxygenase 2 (hIDO2) with a Ki of 0.97 μM.

GNF5-amido-Me, the moiety based on GNF5 (ABL inhibitor),binds through a linker to the IAP ligand forming SNIPER[1].